JOHNSON & JOHNSON — 13F Holdings & Portfolio
CIK 200406 · latest 13F-HR filed 2026-05-13
JOHNSON & JOHNSON manages $652.4M in 13F-reported U.S. long-equity assets across 16 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are PTGX (39.57%), NBTX (26.61%), MGTX (8.82%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 1 new position, exited 2, added to 8, and trimmed 6.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$652.4M
Long-equity book
16
Distinct positions
2026-03-31
Filed 2026-05-13
+1 / −2 / ↑8 / ↓6
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- Protagonist Therapeutics Inc.$44.2M +20.7%
- Nanobiotix S.A.$43.6M +33.5%
- CVRx, Inc.$9.5M +33.2%
- MeiraGTx Holdings plc$4.7M +8.9%
- Contineum Therapeutics Inc.$3.2M +14.3%
Top Trims
- Legend Biotech Corporation-$3.0M -16.8%
- Xencor, Inc.-$2.4M -21.2%
- Procept BioRobotics Corporation-$2.3M -20.5%
- Nano-X Imaging Ltd.-$255.1K -57.4%
- Standard BioTools, Inc.-$112.5K -28.2%
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | Protagonist Therapeutics Inc. | PTGX | 74366E102 | $258.1M | 39.57% | 2,449,183 | SH |
| 2 | Nanobiotix S.A. | NBTX | 63009J107 | $173.6M | 26.61% | 5,623,816 | SH |
| 3 | MeiraGTx Holdings plc | MGTX | G59665102 | $57.5M | 8.82% | 6,641,064 | SH |
| 4 | Rapport Therapeutics, Inc. | RAPP | 75383L102 | $55.8M | 8.56% | 1,784,517 | SH |
| 5 | CVRx, Inc. | CVRX | 126638105 | $38.1M | 5.84% | 4,024,861 | SH |
| 6 | Contineum Therapeutics Inc. | CTNM | 21217B100 | $25.8M | 3.96% | 1,979,173 | SH |
| 7 | Legend Biotech Corporation | LEGN | 52490G102 | $14.7M | 2.26% | 814,586 | SH |
| 8 | Xencor, Inc. | XNCR | 98401F105 | $9.0M | 1.38% | 748,062 | SH |
| 9 | Procept BioRobotics Corporation | PRCT | 74276L105 | $9.0M | 1.37% | 357,939 | SH |
| 10 | Fate Therapeutics, Inc. | FATE | 31189P102 | $4.1M | 0.62% | 3,379,064 | SH |
| 11 | Neumora Therapeutics, Inc. | NMRA | 640979100 | $3.6M | 0.55% | 1,849,445 | SH |
| 12 | Rallybio Corporation | RLYB | 75120L209 | $1.4M | 0.21% | 152,901 | SH |
| 13 | Vor Biopharma, Inc. | VOR | 929033207 | $958.6K | 0.15% | 53,732 | SH |
| 14 | Standard BioTools, Inc. | LAB | 34385P108 | $286.8K | 0.04% | 311,967 | SH |
| 15 | Nano-X Imaging Ltd. | NNOX | M70700105 | $189.7K | 0.03% | 83,554 | SH |
| 16 | Adicet Bio, Inc. | ACET | 007002207 | $155.1K | 0.02% | 22,779 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-13 | $652.4M | 16 | 0000904454-26-000280 |
| 2025-12-31 | 2026-03-18 | $555.0M | 17 | 0000904454-26-000192 |
| 2025-09-30 | 2026-03-18 | $503.9M | 20 | 0000904454-26-000190 |